What is the global market size of Circulating Tumor Cell Market?

Global Circulating Tumor Cell Market size was valued at USD 10.32 Billion in 2022 and is poised to grow from USD 11.7 Billion in 2023 to USD 31.85 Billion by 2031, at a CAGR of 10.3% during the forecast period (2024-2031).

Circulating Tumor Cell Market Size, Share, Growth Analysis, By Product(Kits & Reagents, Blood Collection Tubes, Devices or Systems), By Specimen(Blood, Bone Marrow, other body fluid), By Technology(CTC Detection (Immunocapture, Size-based separation, Density Based Separation, Combined Methods)), By Application(Clinical Liquid Biopsy (Risk Assessment, Screening and Monitoring), Research (Cancer Stem Cell, Drug Therapy Development)), By End User(Hospitals & Clinics, Research & Academic Institutes, Diagnostic Centers), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35H2232 | Region: Global | Published Date: June, 2024
Pages: 219 | Tables: 150 | Figures: 78

Circulating Tumor Cell Market News

In March 2024, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration.

In January 2024, Veracyte announced that it has reached a definitive agreement to acquire C2i Genomics, expanding its diagnostics platform to include whole-genome minimal residual disease (MRD) detection capabilities from cell-free DNA (cfDNA) in liquid biopsies. The MRD testing that C2i offers uses artificial intelligence (AI) to create circulating tumor DNA signatures by comparing the genomics of the patient’s tumor and blood, disposing of the need for bespoke biomarker panels.
In January 2024, Allogene Therapeutics Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products, and Foresight Diagnostics, the leader in the development of ultra-sensitive liquid biopsy circulating tumor DNA (ctDNA) detection announced a strategic partnership to develop a minimal residual disease (MRD) in-vitro diagnostic (IVD) to determine eligibility in ALPHA3, the first pivotal trial for first line (1L) consolidation treatment of large B-cell lymphoma (LBCL).

Circulating Tumor Cell Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Circulating Tumor Cell Market size was valued at USD 10.32 Billion in 2022 and is poised to grow from USD 11.38 Billion in 2023 to USD 24.94 Billion by 2031, at a CAGR of 10.3% during the forecast period (2024-2031).

The competitive environment of the Circulating Tumor Cell market is dynamic and characterised by using the presence of key industry players actively shaping the market dynamics. Companies play pivotal roles, conducting strategic tasks to maintain and decorate their market positions. Ongoing studies and development activities focused on technological advancements and the creation of innovative CTC analysis answers are well-known. 'Janssen Diagnostics (Johnson & Johnson)', 'Sysmex America, Inc.', 'Qiagen', 'Roche Diagnostics', 'BD (Becton, Dickinson and Company)', 'Macrogenics, Inc.', 'Personalis, Inc.', 'ANGLE PLC', 'ApoCell, Inc.', 'RareCyte, Inc.', 'Exosomedx', 'Grail, Inc.', 'Invivoscribe Technologies, LLC', 'Epic Sciences, Inc.', 'Circulating Biomarkers LLC', 'ClariCell, Inc.', 'Thrive Earlier Detection', 'Ellumen', 'Hera BioLabs', 'CellMax Life Technologies'

The growing occurrence of cancer internationally has heightened the call for superior diagnostic equipment, with CTC evaluation emerging as a non-invasive and precious method for cancer detection and tracking. The emphasis on customized medicine and the want for early most cancers diagnosis similarly as the adoption of CTC technologies.

Rising Shift Towards The Integration Of Ctc Analysis Into Routine Clinical Practice: The discernible shift toward the combination of CTC evaluation into ordinary medical exercise, pushed with the aid of its potential for real-time tracking of cancer progression and remedy reaction. The ongoing improvement of progressive technologies, which includes microfluidic systems and superior molecular detection methods, displays a fashion closer to higher precision and sensitivity in CTC analysis. Moreover, the growing cognizance of liquid biopsy methods in cancer diagnostics amplifies the significance of CTCs as valuable biomarkers.

North America is poised to dominate the Circulating Tumor Cell (CTC) market. This dominance can be attributed to the location's advanced healthcare infrastructure, widespread research and development activities, and excessive prevalence of most cancer cases. Robust assist from healthcare establishments and a nicely-hooked up regulatory framework contribute to the sizeable adoption of CTC technologies, positioning North America as a leader in the market.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Circulating Tumor Cell Market News

Circulating Tumor Cell Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Circulating Tumor Cell Market?

Who are the key vendors in the Circulating Tumor Cell Market?

What is the key driver of Circulating Tumor Cell Market?

What is the key market trend for Circulating Tumor Cell Market?

Which region accounted for the largest share in Circulating Tumor Cell Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300